Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2020

View Archived Issues

First-in-human study tests BI-764524 in diabetic macular ischemia

Akeso begins first-in-human study of AK-120 for atopic dermatitis

JS InnoPharm evaluates JSI-1187 for advanced solid tumors with MAPK pathway mutations

Placental attachment theory

CH-7233163: an EGFR inhibitor active against osimertinib-resistant EGFR-T790M/C797S mutations

Novel CTH-004 CAR T cells for the treatment of ovarian cancer

Machine learning, GWAS divide and conquer PCOS

TN1-006: a gene therapy-mediated cardiac reprogramming candidate with potential for MI treatment

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

CECSi cells show promising preclinical results for the treatment of bullous keratopathy

New gamma-secretase inhibitors identified at Roche

Lynk Pharmaceuticals patents Janus kinase inhibitors

Dual CACNA2D1/mu-opioid receptor ligands discovered at Esteve

Emerald Health Biotechnology Espana identifies monoglyceride lipase inhibitors

FDA approves IND for phase II study of antroquinonol in patients with COVID-19

Phase I study of DS-1062 expanded to include patients with TNBC

Menarini plans phase Ib/II study of MEN-1611 in metastatic colorectal cancer

FDA clears initiation of phase III trial of siltuximab for COVID-19-associated ARDS

Early positive data for BNT-162b1 vaccine candidate against SARS-CoV-2

Recruitment starts in phase II study of DUR-928 in COVID-19 with acute liver or kidney injury

European Commission approves canagliflozin label update

Promising efficacy of SJP-1602 in models of TNBC

RO-7297089 begins first-in-human study for relapsed or refractory multiple myeloma

Chinese phase I study evaluates TQB-3558 for solid tumors

European Commission approves Janssen's Ebola vaccine regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...